Search Results

You are looking at 1 - 10 of 181 items for :

  • "metformin" x
Clear All
Free access

Xianghui Meng, Shuhang Xu, Guofang Chen, Michael Derwahl and Chao Liu

Introduction Metformin, the most widely used antidiabetic drug, is considered as the cornerstone of type 2 diabetes treatments. Surprisingly, a few years ago, it has been reported that serum TSH level in hypothyroid patients decreased in

Free access

Xuemei Tang, Jingwen Li, Wei Xiang, Ye Cui, Bin Xie, Xiaodong Wang, Zihui Xu and Lixia Gan

Introduction Metformin is the first-line antihyperglycemia agent for T2DM patients. The mechanisms by which metformin improves glycemic control is mainly by reducing hepatic glucose production, and to a lesser extent, via enhancing peripheral

Free access

Mi-Hyun Kim, Jae-Hwan Jee, Sunyoung Park, Myung-Shik Lee, Kwang-Won Kim and Moon-Kyu Lee

). Metformin, a biguanide that was introduced as an anti-diabetic agent, acts through inhibition of hepatic gluconeogenesis and stimulation of glucose uptake into peripheral tissues ( Sarabia et al . 1992 , Radziuk et al . 1997 ). Recently, metformin has

Free access

Bee K Tan, Jing Chen, Raghu Adya, Manjunath Ramanjaneya, Vanlata Patel and Harpal S Randeva

in subcutaneous and omental adipose tissue(s) of women with PCOS. Furthermore, we studied the effects of glucose and metformin on adipolin protein production in human subcutaneous adipose tissue explants. Subjects and methods Subjects All women with

Free access

Min Hu, Yuehui Zhang, Jiaxing Feng, Xue Xu, Jiao Zhang, Wei Zhao, Xiaozhu Guo, Juan Li, Edvin Vestin, Peng Cui, Xin Li, Xiao-ke Wu, Mats Brännström, Linus R Shao and Håkan Billig

et al. 2013 , Tapia-Pizarro et al. 2017 ), it remains to be determined whether suppression of MAPK/ERK signaling occurs in the endometrium and whether such dysregulation can negatively impact uterine function under PCOS conditions. Metformin is

Full access

Eloise A Bradley, Dino Premilovac, Andrew C Betik, Donghua Hu, Emily Attrill, Stephen M Richards, Stephen Rattigan and Michelle A Keske

Introduction Metformin is the most common first-line oral glucose-lowering pharmacological therapy for people with type 2 diabetes ( Bailey & Turner 1996 , Gunton & Twigg 2003 , Inzucchi et al. 2015 a , b ). It is primarily known for

Free access

Gary J Remington, Celine Teo, Virginia Wilson, Araba Chintoh, Melanie Guenette, Zohra Ahsan, Adria Giacca and Margaret K Hahn

remains as to whether anti-diabetic drugs are efficacious in reversing these direct molecular effects. Metformin (Met), a first-line treatment in the general population for pre-diabetes and DM2 ( Canadian Diabetes Association Clinical Practice Guidelines

Full access

Daniela Álvarez, Karina Ceballo, Sofía Olguín, Jonathan Martinez-Pinto, Manuel Maliqueo, Daniela Fernandois, Ramón Sotomayor-Zárate and Gonzalo Cruz

. Administration of metformin (a biguanide used to treat insulin resistance and diabetes mellitus 2) to obese pregnant rats reportedly reduces fetal liver inflammation ( Harris et al. 2016 ), preventing liver alterations developing in offspring growing in an

Free access

Hong Xu, Yang Zhou, Yongxia Liu, Jian Ping, Qiyang Shou, Fangming Chen and Ru Ruo

the inactive state (GPb). The activation of GS and the depletion of GPa finally result in the stimulation of glycogen synthesis ( Agius 2015 ). Metformin, a potent biguanide hypoglycemic agent, has been clinically used for over five decades and is

Free access

Piotr Zabielski, Marta Chacinska, Karol Charkiewicz, Marcin Baranowski, Jan Gorski and Agnieszka U Blachnio-Zabielska

of associated enzymes and correlate lipid variables with skeletal muscle IR in HFD-fed rats. We used the well-defined experimental model of HFD-induced skeletal muscle IR in rat and employed commonly prescribed insulin sensitizer, metformin, to